Why Third-Party Manufacturing Took Over Indian Pharma: 3 Structural Reasons

Twenty years ago, a pharmaceutical company in India owned a plant. Today most of them do not, and the ones selling the most medicine are often the ones manufacturing the least of it themselves. That shift did not happen because someone had an idea. It happened because of three specific pressures — and understanding them tells you more about how this industry works than any brochure will.

For the mechanics, read how third-party manufacturing works. This page is about why it took over.

1. Compliance got expensive, and it never stops costing

Schedule M and WHO-GMP norms turned a factory from a shed with machines into a validated, documented, permanently inspection-ready operation. Clean rooms, HVAC, water systems, stability chambers, a QC lab, qualified persons, documentation.

The important part is that this cost is fixed and continuous. It runs whether you produced anything that month or not. A brand owner selling ₹50 lakh a month cannot carry that. A manufacturer running several companies' batches through the same validated line can carry it comfortably — because the same compliance overhead is spread across everybody's production.

That single economic fact created the contract manufacturing industry.

2. Regulation forced specialisation by dosage form

You cannot legally make everything in one building. Beta-lactam antibiotics require physically segregated premises. Ophthalmics and injectables need sterile lines. Ayurvedic products are licensed under an entirely separate Act.

So a company wanting to sell tablets, an antibiotic, an eye drop and an injectable is not contemplating one factory. It is contemplating four sets of premises, four validation programmes, four licences. Almost nobody builds that. They build one, and outsource the rest — which is why even large manufacturers are themselves customers of other manufacturers.

Specialisation was not a business choice. Regulation made it structural.

3. The PCD model created thousands of brand owners with no plant

The PCD franchise system put pharmaceutical distribution into the hands of thousands of small operators across Tier 2 and Tier 3 India — people with doctor relationships and territory knowledge, and no interest whatsoever in owning a factory.

Every one of them needed products under a brand. None of them were going to manufacture. That demand had to land somewhere, and it landed on contract manufacturers. The growth of third-party manufacturing and the growth of PCD franchise are the same story told from two ends.

What actually changed: risk moved

Third-party manufacturing did not make medicine cheaper to produce. It moved where the risk sits. Capital risk, idle-capacity risk and compliance risk moved to the manufacturer, who can spread them across many customers. Market risk — will this product sell — stayed with the brand owner, who is the only one who can influence it.

That is a genuinely efficient arrangement, and it is why it won. Each party carries the risk it can actually manage.

What it means for you

Mostly this: the plant making your medicine is probably not owned by the company whose name is on the box. That is normal and it is legal. It only becomes a problem when nobody will tell you which plant it is.

Which is why the useful question was never "do you have WHO-GMP." It is: which site, at what address, certified for which dosage forms, under which licence number. The industry grew up around outsourcing. The only thing that separates companies now is whether they are straight about it.

Who manufactures for Vibcare

Vibcare Pharma is a PCD pharma franchise company. It does not manufacture. Manufacturing is done by Vibcare Healthcare Private Limited — a separate company under the same ownership, with its own plant, licences and website.

The site: Khasra No. 6/2/2, Kota Road, Dabkori, Panchkula 134103, Haryana. WHO-GMP certified by the State Drugs Controller-cum-Licensing Authority, FDA Haryana. Site Certificate No. 1/182-1Drug-I-2024, issued 24 October 2024. Licences MLF252023HR000004 and MLF282023HR000005, valid to 7 May 2028. 100,000 sq ft clean room, 750+ drug approvals.

Certified for four dosage forms: tablets, capsules and external preparations — all non beta-lactam — and oral liquids. It does not make beta-lactam antibiotics, ophthalmics, injectables, softgels, IV liquids, respules, DPI, nasal sprays, protein powders and sachets, or ayurvedic products, because it is not certified for them — which is reason 2 on this page, happening to us.

Interested in the other end of this story? A PCD pharma franchise is reason 3 in practice — a monopoly territory selling an existing brand range, from ₹25,000, with no plant to build. Here is the difference.

Frequently asked questions

Why has third-party manufacturing grown in India?

Three reasons. Compliance became a large fixed cost that only makes sense spread across many customers' production. Regulation forces different dosage forms into different premises, so no single plant covers a broad range. And the PCD franchise model created thousands of brand owners who never intended to own a factory.

Why do pharma companies not own their own plants?

Because a compliant plant costs crores in capital plus a permanent compliance and QC team, and it loses money whenever it runs below capacity. Contract manufacturing converts that fixed cost into a per-batch cost, so capital goes into stock and market building instead of fixed assets.

Is third-party manufacturing legal in India?

Yes. The product is manufactured under the manufacturer's drug licence, at their certified premises, and packed under the brand owner's name. The manufacturing licence number and site address are printed on every pack. It is how a large share of medicine sold in India is legitimately produced.

Will third-party manufacturing keep growing?

The pressures behind it have not reversed. Compliance costs are rising, not falling; dosage-form segregation is regulation; and the PCD model continues to add brand owners with no manufacturing intent. The structural logic that created the industry is still fully intact.